| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Hans-Jürgen Wester | Q128303541 |
| P2093 | author name string | Horst Kessler | |
| Markus Schwaiger | |||
| Ambros J Beer | |||
| P2860 | cites work | Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD | Q24805375 |
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| New perspectives in cell adhesion: RGD and integrins | Q28280381 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Mechanisms of angiogenesis | Q29547485 | ||
| 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression | Q30497615 | ||
| Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. | Q32053981 | ||
| Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography | Q33574585 | ||
| Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. | Q34159304 | ||
| Involvement of integrin alpha V gene expression in human melanoma tumorigenicity | Q34222036 | ||
| Pegylation: a novel process for modifying pharmacokinetics | Q34340198 | ||
| Simultaneous PET-MRI: a new approach for functional and morphological imaging | Q34765886 | ||
| Imaging tumour angiogenesis | Q35172997 | ||
| Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development | Q35905013 | ||
| Molecular imaging in the clinical arena | Q36043188 | ||
| Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. | Q36341230 | ||
| Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? | Q36514879 | ||
| Carbon nanotubes as nanomedicines: from toxicology to pharmacology | Q36657144 | ||
| Chemically functionalized carbon nanotubes. | Q36694304 | ||
| 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals | Q37126389 | ||
| Molecular imaging of αvß3 expression in cancer patients. | Q37773781 | ||
| Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism | Q39826304 | ||
| Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature | Q40066441 | ||
| (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression | Q40118679 | ||
| Effects of angiogenesis inhibitors on multistage carcinogenesis in mice | Q41648802 | ||
| Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography | Q43561095 | ||
| Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging | Q43641822 | ||
| Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients | Q43788666 | ||
| Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. | Q44275821 | ||
| Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation | Q44457063 | ||
| MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide | Q44735123 | ||
| [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates | Q44735126 | ||
| Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation | Q44740884 | ||
| Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis | Q44882470 | ||
| Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide | Q45008593 | ||
| MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides | Q45068701 | ||
| Ligands for mapping alphavbeta3-integrin expression in vivo. | Q45986254 | ||
| microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide | Q46115376 | ||
| Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy | Q46192839 | ||
| The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers | Q46365501 | ||
| Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients | Q46639250 | ||
| Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? | Q46837681 | ||
| Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. | Q46852304 | ||
| Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. | Q46872269 | ||
| [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck | Q46897615 | ||
| Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high-sensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard. | Q51294264 | ||
| Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. | Q53530857 | ||
| PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. | Q53540557 | ||
| Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. | Q53686513 | ||
| Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting | Q78143346 | ||
| Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692 | Q80216849 | ||
| In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice | Q81697594 | ||
| Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis | Q83284350 | ||
| Antiangiogenic therapy: a universal chemosensitization strategy for cancer? | Q83854395 | ||
| P304 | page(s) | 48-57 | |
| P577 | publication date | 2011-01-17 | |
| P1433 | published in | Theranostics | Q21051383 |
| P1476 | title | PET Imaging of Integrin αVβ3 Expression | |
| P478 | volume | 1 |
| Q50211346 | 68Gallium-Arginine-Glycine-Aspartic Acid and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Chondroblastic Osteosarcoma of the Skull. |
| Q95360899 | A dual-labeled cRGD-based PET/optical tracer for pre-operative staging and intraoperative treatment of colorectal cancer |
| Q85553370 | A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients |
| Q26851887 | Advance of molecular imaging technology and targeted imaging agent in imaging and therapy |
| Q53072915 | An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients. |
| Q30832796 | Application of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke |
| Q33793550 | Comparison of 18F-AIF-NOTA-PRGD2 and 18F-FDG uptake in lymph node metastasis of differentiated thyroid cancer |
| Q38738606 | Comparison of biological properties of 99mTc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging |
| Q40858096 | Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction |
| Q39104091 | Comparison of three dimeric 18F-AlF-NOTA-RGD tracers |
| Q35629161 | Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice |
| Q38440214 | Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. |
| Q34009539 | Current and future intraoperative imaging strategies to increase radical resection rates in pancreatic cancer surgery |
| Q38864088 | Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD-paclitaxel conjugates for integrin-assisted drug delivery |
| Q39369190 | Efficient construction of PET/fluorescence probe based on sarcophagine cage: an opportunity to integrate diagnosis with treatment |
| Q50877024 | Enzymatic transhalogenation of dendritic RGD peptide constructs with the fluorinase. |
| Q51732415 | Evaluation of a dimeric-cRGD peptide for targeted PET-CT imaging of peripheral angiogenesis in diabetic mice. |
| Q38680000 | Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. |
| Q36931413 | First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination |
| Q90677006 | Functional In Vivo Imaging of Tumors |
| Q35988082 | How Does the Patient Benefit from Clinical PET? |
| Q34506838 | Image guided biodistribution and pharmacokinetic studies of theranostics |
| Q27693338 | In vivo imaging of therapy-induced anti-cancer immune responses in humans |
| Q38700087 | Integrin Ligands with α/β-Hybrid Peptide Structure: Design, Bioactivity, and Conformational Aspects |
| Q34786949 | Integrin Targeted Imaging and Therapy |
| Q38501776 | Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation |
| Q37236103 | Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics |
| Q36663342 | Lewis acid-assisted isotopic 18F-19F exchange in BODIPY dyes: facile generation of positron emission tomography/fluorescence dual modality agents for tumor imaging |
| Q36069595 | Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V. |
| Q37663675 | Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors |
| Q38929240 | MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice |
| Q50993912 | MicroPET/CT imaging of αvβ₃ integrin via a novel ⁶⁸Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. |
| Q35897573 | Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications |
| Q26851449 | Nanotheranostics for personalized medicine |
| Q34028690 | Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe. |
| Q35224462 | New Methods for Labeling RGD Peptides with Bromine-76. |
| Q53085688 | One-step radiosynthesis of 4-nitrophenyl 2-[(18) F]fluoropropionate ([(18) F]NFP); improved preparation of radiolabeled peptides for PET imaging. |
| Q46093885 | Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding αv β3 integrins. |
| Q35641937 | PET Imaging of Integrin Positive Tumors Using F Labeled Knottin Peptides |
| Q36221080 | PET Tracers for Clinical Imaging of Breast Cancer. |
| Q36997603 | PET imaging of inflammation biomarkers |
| Q36820918 | Photosensitizer-conjugated silica-coated gold nanoclusters for fluorescence imaging-guided photodynamic therapy |
| Q36394255 | Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4. |
| Q28729872 | Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model |
| Q36107186 | Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model |
| Q38166986 | RGD-based PET tracers for imaging receptor integrin αv β3 expression |
| Q26801806 | Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins |
| Q28072021 | Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging |
| Q38171376 | Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. |
| Q39373913 | Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging |
| Q41766834 | Stereotactic Comparison Study of (18)F-Alfatide and (18)F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model |
| Q41593876 | Synthesis and evaluation of an (18) F-labeled derivative of F3 for targeting surface-expressed nucleolin in cancer and tumor endothelial cells. |
| Q41949498 | Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of α V β 3 Integrin Activity |
| Q34974123 | Targeted nanoprobes reveal early time point kinetics in vivo by time-resolved MRI |
| Q30395463 | Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging |
| Q36052972 | The efficient synthesis and biological evaluation of novel bi-functionalized sarcophagine for (64)cu radiopharmaceuticals |
| Q40066911 | Theranostic cRGD-BioShuttle Constructs Containing Temozolomide- and Cy7 For NIR-Imaging and Therapy |
| Q35224469 | Transforming a Targeted Porphyrin Theranostic Agent into a PET Imaging Probe for Cancer. |
Search more.